Unlock instant, AI-driven research and patent intelligence for your innovation.

Treating cancer by blocking the interaction of tim-3 and its ligand

A TIM-3, cancer technology, applied in the direction of antibody medical components, antibodies, pharmaceutical formulations, etc., can solve the problems of data inconsistency and unreliability

Pending Publication Date: 2020-05-26
TRUEBINDING INC
View PDF23 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Early efforts have been made to identify TIM-3 ligands in this regulation, but the data are inconsistent and unreliable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treating cancer by blocking the interaction of tim-3 and its ligand
  • Treating cancer by blocking the interaction of tim-3 and its ligand
  • Treating cancer by blocking the interaction of tim-3 and its ligand

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0224] Example 1. Generation of Cell Lines Overexpressing GAl3

[0225] The mouse B-lymphoma cell line A20 obtained from the American Tissue and Cell Culture Collection (ATCC, Manassas, VA) was encoded with either a Flag-tagged human Gal3 protein or a Flag-tagged human PDL1 protein. Transfection of nucleic acid constructs. The construct additionally contains a marker for antibiotic resistance. Transformed cells were selected based on antibiotic resistance to form A20 cells stably expressing Flag-tagged human Gal3 protein (A20 Gal3 cells) or A20 cells stably expressing Flag-tagged human PDL1 protein (A20 hPDL1 cells).

Embodiment 2

[0226] Example 2.GA13 specifically binds to TIM-3

[0227] This example describes various assays that have been performed to assess the interaction between Gal3 and TIM-3.

[0228] Binding assay--co-immunoprecipitation

[0229] Co-immunoprecipitation experiments were performed to test whether TIM-3 specifically interacts with Gal3. 293T cells were co-transfected with plasmids encoding HA-tagged TIM-3 and plasmids encoding Flag-tagged Gal3, Flag-tagged Gal9 or Flag-tagged CEACAM1. Transfections were performed using Lipofectamine 3000 (Waltham, MA) following the manufacturer's protocol. Transfected cells were grown overnight, then washed and lysed in 1 ml lysis buffer. The lysed cells were centrifuged and the supernatant (lysate) collected. The lysates were prepared and separated on SDS PAGE, and were analyzed with anti-HA antibody ( Figure 1A ) and anti-Flag antibody ( Figure 1B ) to detect. Both anti-Flag antibody and anti-HA antibody were purchased from Sigma. Fi...

Embodiment 3

[0243] Example 3. Overexpression of Gal3 inhibits T cell activation

[0244] This example describes experiments performed to assess the functional properties of Gal3 overexpression in A20 cells.

[0245] A20 clones #41, #31 and #15 stably overexpressing hGal3 were generated as described above. Figure 6A Results of flow cytometry analysis showing hGal3 expression levels in these clones are shown. Cells of A20 or A20 Gal3 clones were mixed with mouse DO11.10 T cells. The mixture was placed in each well of a 96-well plate, and OVA323-339 peptide (Invivogen, San Diego, CA) was added to the plate. After overnight incubation, supernatants were used to measure IL-2 production by T cells by ELISA (ThermoFisher Scientific). Such as Figure 6B shows that IL-2 production by mouse DO11.10 T cells was significantly reduced when mixed with any of the three mouse A20 cell clones compared to when T cells were mixed with parental A20 cells ( Figure 6B ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Provided herein are methods of activating immune response and / or treating cancer in a patient comprising administering to the patient a Gal3:TIM-3 inhibitor that interferes with the interaction between Gal3 and TIM-3, where said inhibitor is administered in an amount sufficient to activate immune response. Also provided are a humanized anti-Gal3 antibodies that can block the interaction between Gal3 and TIM3 and methods of using the anti-Gal3 antibody to treat cancer. Methods for determining if a patient's cancer is suitable for treatment with a Gal3:TIM-3 inhibitor and methods for selecting compounds that can block interaction between Gal3 and TIM-3, activating immune response and / or treating cancer are also provided.

Description

[0001] related application [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 536,886, filed July 25, 2017. Said provisional application is hereby incorporated by reference in its entirety for all purposes. Background technique [0003] Human cancers have many genetic and epigenetic alterations that generate neoantigens potentially capable of being recognized by the immune system. Although an endogenous immune response to cancer is observed in preclinical models and patients, this response is ineffective, and established cancers are often considered "self" and tolerated by the immune system. In addition, tumors may actively suppress host immune responses by several different mechanisms. Among these mechanisms, tumors can evade immune destruction using immune checkpoints, which involve various negative regulators of the immune system that normally terminate immune responses to mitigate collateral tissue damage. [0004] T cell immunoglobulin ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K39/00A61K39/395A61P35/00C07K14/705C07K16/28G01N33/574
CPCC07K14/705G01N33/574A61P35/00G01N33/505G01N2500/02G01N2500/10G01N2500/20A61K2039/505C07K16/2851C07K2317/34C07K2317/76A61P35/04A61K45/06A61K2039/545A61K9/0019C07K16/2803C07K2317/21C07K2317/30C07K2317/55G01N33/57492
Inventor D·孙Y·王
Owner TRUEBINDING INC